Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 200

1.

Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.

Paskett E, Herndon J 2nd, Donohue K, Naughton M, Grubbs S, Pavy M, Hensley M, Stark N, Kornblith A, Bittoni M; for Cancer and Leukemia Group B.

Cancer. 2009 Mar 1;115(5):1109-20. doi: 10.1002/cncr.24140.

PMID:
19170232
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
[PubMed - indexed for MEDLINE]
Free Article
3.

Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.

Paskett ED, Herndon JE 2nd, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA; Cancer and Leukemia Group B.

Psychooncology. 2008 Nov;17(11):1108-20. doi: 10.1002/pon.1329.

PMID:
18314912
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors.

Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA.

Recent Results Cancer Res. 1998;152:396-411.

PMID:
9928575
[PubMed - indexed for MEDLINE]
5.

Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.

Land SR, Kopec JA, Yothers G, Anderson S, Day R, Tang G, Ganz PA, Fisher B, Wolmark N.

Breast Cancer Res Treat. 2004 Jul;86(2):153-64.

PMID:
15319567
[PubMed - indexed for MEDLINE]
6.

Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.

Bottomley A, Biganzoli L, Cufer T, Coleman RE, Coens C, Efficace F, Calvert HA, Gamucci T, Twelves C, Fargeot P, Piccart M; European Organization for Research and Treatment of Cancer Breast Cancer Group.

J Clin Oncol. 2004 Jul 1;22(13):2576-86.

PMID:
15226325
[PubMed - indexed for MEDLINE]
7.
8.

Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS.

J Clin Oncol. 2008 Mar 10;26(8):1223-30. doi: 10.1200/JCO.2007.11.8877. Epub 2008 Jan 28.

PMID:
18227530
[PubMed - indexed for MEDLINE]
9.

Breast cancer: relationship between menopausal symptoms, physiologic health effects of cancer treatment and physical constraints on quality of life in long-term survivors.

Schultz PN, Klein MJ, Beck ML, Stava C, Sellin RV.

J Clin Nurs. 2005 Feb;14(2):204-11.

PMID:
15669929
[PubMed - indexed for MEDLINE]
10.

Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.

Aisner J, Cirrincione C, Perloff M, Perry M, Budman D, Abrams J, Panasci L, Muss H, Citron M, Holland J, et al.

J Clin Oncol. 1995 Jun;13(6):1443-52.

PMID:
7751891
[PubMed - indexed for MEDLINE]
11.

Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.

Joly F, Espié M, Marty M, Héron JF, Henry-Amar M.

Br J Cancer. 2000 Sep;83(5):577-82.

PMID:
10944595
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.

Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E.

Cancer. 2005 Oct 15;104(8):1580-9.

PMID:
16118805
[PubMed - indexed for MEDLINE]
Free Article
13.

Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.

Fumoleau P, Chauvin F, Namer M, Bugat R, Tubiana-Hulin M, Guastalla JP, Delozier T, Kerbrat P, Devaux Y, Bonneterre J, Filleul A, Clavel M.

J Clin Oncol. 2001 Feb 1;19(3):612-20.

PMID:
11157010
[PubMed - indexed for MEDLINE]
14.

Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy.

Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Titus-Ernstoff L, Skalla K, Bakitas M, Silberfarb PM.

J Clin Oncol. 2005 Jul 1;23(19):4399-405.

PMID:
15994149
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM.

J Clin Oncol. 2002 Jan 15;20(2):485-93.

PMID:
11786578
[PubMed - indexed for MEDLINE]
16.

Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA; Cancer and Leukemia Group B.

Cancer Treat Rev. 2008 May;34(3):223-30. doi: 10.1016/j.ctrv.2007.11.004. Epub 2008 Jan 30.

PMID:
18234424
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.

Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T, Wilking N, Bergh J; Scandinavian Breast Group Study 9401.

J Clin Oncol. 2003 Oct 1;21(19):3659-64.

PMID:
14512398
[PubMed - indexed for MEDLINE]
18.

Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.

Klassen AF, Miller A, Fine S.

Pediatrics. 2004 Nov;114(5):e541-7.

PMID:
15520087
[PubMed - indexed for MEDLINE]
19.

The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.

Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, Zander AR, Koch U.

Patient Educ Couns. 2007 Apr;66(1):108-18. Epub 2007 Feb 21.

PMID:
17320337
[PubMed - indexed for MEDLINE]
20.

Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens.

Berger AM, Lockhart K, Agrawal S.

Oncol Nurs Forum. 2009 Sep;36(5):563-70. doi: 10.1188/09.ONF.563-570.

PMID:
19726396
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk